top of page
Technologies NGS

ATOM-Seq   Technologies


Adapter Template Oligo-Mediated Sequencing

A Revolutionary New DNA-Capture Method for Next Generation Sequencing

ATOM-Seq Technological Overview

Our XCeloSeq NGS library preparation kits employ the novel, patented, GeneFirst breakthrough technology, ATOM-Seq, which uses a simple and elegant chemistry to capture DNA, where sample DNA molecules act as primers and their 3’ ends are extended by a polymerase.


ATOM-Seq incorporates Unique Molecular Identifiers (UMIs) and universal adapter sequences directly into available 3' ends of every original sample molecule.

ATO Reaction

Hands-on Time:

5 min


Incubation Time: 70 min

Sample DNA or cDNA is combined with the Adapter Template Oligo

The DNA molecules anneal to the 3’ end of the ATO.

After annealing, a polymerase extends the original molecule, using the ATO sequence as a template.

Using its ATO template, the polymerase incorporates both a Unique Molecular Identifier (UMI) and a universal priming site into the captured molecule.

Linear Amplification


Hands-on Time:

5 min

Incubation Time: 35 min

A universal primer is used for multiple rounds of linear amplification, improving error correction. This also means that all original copies can be represented in downstream reactions, even when the linear product is divided between sense- and antisense-strand targeted enrichment

Downstream Protocols

Protocol time includes all steps shown, from initial ATO Reaction to final, bead-purified library.

Targeted cfDNA

Protocol Time:

Total: <6 hours

Hands-on: 1.5 hours

Input Amount:

Recommended: 5-50ng

Minimum: 1ng


Allele frequency: ≥0.1%

Targeted RNA


Protocol Time:

Total: <7.5 hours

Hands-on: 2 hours


Input Amount:

Recommended: 5-200ng

Minimum: 1ng


Both known and

unknown gene fusions

Whole Genome

Protocol Time:

Total: 4h 45m

Hands-on: 2h

Input Amount:

Recommended: 5-50ng

Minimum: 1ng


Key Advantages

This unique approach is ligation free and is set apart from conventional PCR-based approaches by requiring only a single target-specific primer for enrichment. This offers numerous advantages that make ATOM-Seq particularly well suited to challenging clinical material such as cell-free DNA (cfDNA) from liquid biopsies or FFPE-preserved RNA.

MicrosoftTeams-image (5).png

Ticks indicate aspects the technologies can do.

Dashes indicate the aspects of the technologies which are inefficient.

Crosses indicate aspects the technologies cannot or have not been optimised to do.

bottom of page